← Back to Treatments
🏅 FDA Orphan Designation

Wilate

von Willebrand Factor/Coagulation Factor VIII Complex (Human)

Manufacturer: Octapharma USA, Inc.

Indicated for:
Hematological disease associated with an acquired peripheral neuropathyOrphanVon Willebrand disease type 3Von Willebrand disease

FDA-Approved Indications (3)

Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known…

Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known…

Population: patients with severe VWD; patients with mild or moderate VWD where desmopressin is ineffective or contraindicated

Routine prophylaxis to reduce the frequency of bleeding episodes in children 6 years of age and older and adults with von Willebrand disease

Population: children 6 years of age and older and adults

Indications & Usage

Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated ||| Routine prophylaxis to reduce the frequency of bleeding episodes in children 6 years of age and older and adults with von Willebrand disease

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.